Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 7:31 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 340 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Essential Amino Acid+ Clear all
Completed Phase 1 Interventional

Combination Chemotherapy Followed By Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Severe Aplastic Anemia

NCT00054236
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, filgrastim, cyclophosphamide, fludarabine phosphate, umbilical cord blood transplantation, methylprednisolone
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Up to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 26, 2020 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitric Oxide and the Autonomic Nervous System

NCT00178919
View directory record Official record
Conditions
Hypertension, Pure Autonomic Failure
Interventions
L-NMMA, Trimethaphan
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 4 Interventional Results available

Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction

NCT02874794
View directory record Official record
Conditions
Heart Failure and Reduced Ejection Fraction
Interventions
LCZ696 (sacubitril/valsartan), Enalapril, Placebo of Enalapril, Placebo of LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
81
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 69 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Alemtuzumab and Combination Chemotherapy Followed By Donor Lymphocytes in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer

NCT00104975
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions
alemtuzumab, therapeutic allogeneic lymphocytes, fludarabine phosphate, melphalan, tacrolimus, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Tryptophan MRI in People With Schizophrenia and Healthy Controls

NCT02067975
View directory record Official record
Conditions
Schizophrenia
Interventions
Tryptophan, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 55 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nutritional Strategies to Augment the Postprandial Muscle Protein Synthetic Response to the Ingestion of a Low Dose of Protein in Middle-aged Women

NCT02918981
View directory record Official record
Conditions
Aging
Interventions
Resistance Exercise, 14 g Whey protein, 6.6 g Whey protein + 1.25 g leucine, 4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides, 6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline, Water control
Behavioral · Dietary Supplement · Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
20 Years to 79 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Early Phase 1 Interventional

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis

NCT05705414
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 64 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

NCT00072826
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oxypurinol, L-NMMA, Acetylcholine
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Not applicable Interventional

A Collection of Case Studies in Infants With UCD to Evaluate Infant Growth and the Safety of a New Medical Food for UCD

NCT03911089
View directory record Official record
Conditions
Urea Cycle Disorder, Inborn Errors of Metabolism
Interventions
UCD Anamix Infant
Other
Lead sponsor
Nutricia Research
Industry
Eligibility
Up to 30 Days
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 8, 2021 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Lopinavir/Ritonavir on Endothelial Function

NCT00076414
View directory record Official record
Conditions
Healthy
Interventions
Acetylcholine, L-NMMA
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dietary Intake and Circulating Levels of Branched Chain Amino Acids

NCT02110602
View directory record Official record
Conditions
Dietary Intake of Branched Chain Amino Acids
Interventions
Diet high in amino acid levels, Diet low in amino acid levels
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
20 Years to 40 Years · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Sep 11, 2026, 7:31 PM EDT
Not yet recruiting Early Phase 1 Interventional

Sarcopenia in Chronic Kidney Disease (CKD) Patients

NCT07437053
View directory record Official record
Conditions
Chronic Kidney Disease, Sarcopenia
Interventions
Valine, EEA
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
45 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 11, 2026, 7:31 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Metabolic Effects of Chemical Interactions in Toxicity

NCT00253773
View directory record Official record
Conditions
Oxidative Stress
Interventions
acetominophen, sulfer amino acids; cysteine and methionine
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 12, 2010 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 3 Interventional Results available

Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

NCT02227875
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Mylan's insulin glargine, Lantus®
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
94
States / cities
Chandler, Arizona • Bell Gardens, California • Fresno, California + 84 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 11, 2026, 7:31 PM EDT
Terminated Phase 4 Interventional

The Use of DIOVAN to Reduce Post-Cardioversion Recurrence of Atrial Fibrillation Trial (the DRAFT Trial)

NCT00343499
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
valsartan
Drug
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Ogden, Utah • Salt Lake City, Utah • St. George, Utah
Source: ClinicalTrials.gov public record
Updated Aug 20, 2008 · Synced Sep 11, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial

NCT07202247
View directory record Official record
Conditions
Prostate Carcinoma, Recurrent Prostate Carcinoma
Interventions
Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide
Drug · Behavioral · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
30 Years to 79 Years · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 3 Interventional

Efficacy & Safety of Orally Administered Valsartan/Amlodipine Combo Therapy vs Amlodipine Monotherapy in Patients With Stage II Hypertension

NCT00350168
View directory record Official record
Conditions
Hypertension
Interventions
valsartan + amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
647 participants
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2016 · Synced Sep 11, 2026, 7:31 PM EDT
Recruiting Phase 2 Interventional

Repurposing Valsartan May Protect Against Pulmonary Hypertension

NCT06053580
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Right Heart Failure, Right Ventricular Dysfunction, Pulmonary Vascular Disorder
Interventions
Valsartan 40 mg, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 3, 2026 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nutritional and Contractile Regulation of Muscle Growth

NCT00891696
View directory record Official record
Conditions
Sarcopenia
Interventions
Rapamycin, Amino acid supplementation, Low-intensity resistance exercise, Sodium nitroprusside, Blood flow restriction cuff
Drug · Other · Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 85 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated May 3, 2017 · Synced Sep 11, 2026, 7:31 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Positron Emission Tomography (PET) Imaging of Pancreatic Beta-Cell Mass in Healthy and Type 1 Diabetic Patients

NCT00958997
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
18F-FP-DTBZ (18F-AV-133), Arginine-hydrochloride
Drug · Biological
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2012 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 1 Interventional

Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer

NCT00003451
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
recombinant interferon alfa, recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Sep 11, 2026, 7:31 PM EDT
Completed Phase 4 Interventional

Pregabalin (Lyrica) for the Treatment of Essential Tremor

NCT00584376
View directory record Official record
Conditions
Essential Tremor
Interventions
Pregabalin, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
8
States / cities
Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2012 · Synced Sep 11, 2026, 7:31 PM EDT
Terminated Phase 2 Interventional

Peripheral Stem Cell Transplant in Treating Patients With High-Risk Leukemia

NCT00066417
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic/Myeloproliferative Diseases
Interventions
cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, therapeutic allogeneic lymphocytes, thiotepa, allogeneic bone marrow transplantation, biological therapy, bone marrow ablation with stem cell support, bone marrow transplantation, chemotherapy, leukocyte therapy, non-specific immune-modulator therapy, peripheral blood lymphocyte therapy, peripheral blood stem cell transplantation, radiation therapy
Drug · Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
10 Years to 50 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2013 · Synced Sep 11, 2026, 7:31 PM EDT